Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ODC1 | P11926 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL667646 | 1.00 | — | — | |
| SCHEMBL11885390 | 1.00 | ODC1 (0.41) | ODC1ADRB2ADRB1ADRB3MEN1 | |
| Aminooxyethoxyethoxyethylhydroxylamine SCHEMBL43069 | 1.00 | ODC1 (0.41) | ODC1ADRB2ADRB1ADRB3MEN1 | |
| SCHEMBL758346 | 1.00 | ODC1 (0.41) | ODC1ADRB2ADRB1ADRB3MEN1 | |
| Water SCHEMBL20496293 | 0.96 | ODC1 (0.39) | ODC1ADRB2ADRB1ADRB3MEN1 | |
| SCHEMBL22169531 | 0.89 | ODC1 (0.42) | ODC1ADRB2ADRB1ADRB3MEN1 | |
| SCHEMBL24500071 | 0.86 | ODC1 (0.47) | ODC1ADRB2ADRB1ADRB3MEN1 | |
| SCHEMBL16329755 | 0.86 | ODC1 (0.47) | ODC1ADRB2ADRB1ADRB3MEN1 | |
| SCHEMBL13221671 | 0.86 | ODC1 (0.47) | ODC1ADRB2ADRB1ADRB3MEN1 | |
| SCHEMBL2127510 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12516083-B2 | Nucleophilic catalysts for oxime linkage | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-01-06 | — | — | US | disclosed |
| US-20240335549-A1 | THERAPEUTIC PROTEINS WITH INCREASED HALF-LIFE AND METHODS OF PREPARING SAME | BAXALTA INCORPORATED (US) | 2024-10-10 | — | — | US | disclosed |
| US-11564992-B2 | Nucleophilic catalysts for oxime linkage | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-31 | — | — | US | disclosed |
| US-11564992-B2 | Nucleophilic catalysts for oxime linkage | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-31 | — | — | US | disclosed |
| EP-4023247-A1 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE | Takeda Pharmaceutical Company Limited (JP) | 2022-07-06 | — | — | EP | disclosed |
| EP-4023247-A1 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE | Takeda Pharmaceutical Company Limited (JP) | 2022-07-06 | — | — | EP | disclosed |
| EP-4019049-A1 | METHODS FOR PREPARING THERAPEUTIC PROTEIN-POLYMER CONJUGATES | Takeda Pharmaceutical Company Limited (JP) | 2022-06-29 | — | — | EP | disclosed |
| EP-4019049-A1 | METHODS FOR PREPARING THERAPEUTIC PROTEIN-POLYMER CONJUGATES | Takeda Pharmaceutical Company Limited (JP) | 2022-06-29 | — | — | EP | disclosed |
| US-20220175939-A1 | THERAPEUTIC PROTEINS WITH INCREASED HALF-LIFE AND METHODS OF PREPARING SAME | BAXALTA INCORPORATED (US) | 2022-06-09 | — | — | US | disclosed |
| US-20220175939-A1 | THERAPEUTIC PROTEINS WITH INCREASED HALF-LIFE AND METHODS OF PREPARING SAME | BAXALTA INCORPORATED (US) | 2022-06-09 | — | — | US | disclosed |
| US-20080182969-A1 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080177038-A1 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080177027-A1 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080177027-A1 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080177038-A1 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080153979-A1 | non-natural amino acids are selected from amino acids having protected or masked carbonyl, dicarbonyl, hydroxylamine, or oxime side chains, and amino acid attached to a polyoxyethylene glycol, acrylic polymers or natural polymer; therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2008-06-26 | — | — | US | disclosed |
| US-20080153979-A1 | non-natural amino acids are selected from amino acids having protected or masked carbonyl, dicarbonyl, hydroxylamine, or oxime side chains, and amino acid attached to a polyoxyethylene glycol, acrylic polymers or natural polymer; therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2008-06-26 | — | — | US | disclosed |
| US-7385028-B2 | Modified non-natural amino acid polypeptides typically include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group; therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC (US) | 2008-06-10 | — | — | US | disclosed |
| US-7332571-B2 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332571-B2 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2008-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080177038-A1 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | DNPEP, DAO, PTMS | ODC1 48/4885ADRB2 4130/4885ADRB1 4261/4885 |
| US-11564992-B2 | Nucleophilic catalysts for oxime linkage | LPO, OGA, DAO | ODC1 497/4885ADRB2 4683/4885ADRB1 4649/4885 |
| US-20220175939-A1 | THERAPEUTIC PROTEINS WITH INCREASED HALF-LIFE AND METHODS OF PREPARING SAME | SERPINA6, FCGRT, ALB | ODC1 3526/4885ADRB2 4629/4885ADRB1 4708/4885 |
| US-20080182969-A1 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | DNPEP, DAO, PTMS | ODC1 48/4885ADRB2 4130/4885ADRB1 4261/4885 |
| US-20080177027-A1 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | DNPEP, DAO, PTMS | ODC1 48/4885ADRB2 4130/4885ADRB1 4261/4885 |
| US-20080153979-A1 | non-natural amino acids are selected from amino acids having protected or masked carbonyl, dicarbonyl, hydroxylamine, or oxime side chains, and amino acid attached to a polyoxyethylene glycol, acrylic polymers or natural polymer; therapeutic, diagnostic, and other biotechnology uses | DAO, DNPEP, AADAT | ODC1 42/4885ADRB2 3781/4885ADRB1 4174/4885 |
| US-20240335549-A1 | THERAPEUTIC PROTEINS WITH INCREASED HALF-LIFE AND METHODS OF PREPARING SAME | SERPINA6, FCGRT, ALB | ODC1 3526/4885ADRB2 4629/4885ADRB1 4708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.